Percutaneous Mechanical Circulatory Support Devices Market
Medical Device

13.5% Global CAGR for Percutaneous Mechanical Circulatory Support Devices Market to achieve US$ 3,964.75 Mn by 2027

LivaNova PLC, Inc and Abbott.- Notable Market Players in Percutaneous Mechanical Circulatory Support Devices  Market

The percutaneous mechanical circulatory support devices market is highly competitive in nature with considerable number of players, having a high level of consolidation overall revenue share. Most of the companies operating in the percutaneous mechanical circulatory support devices market are present globally and have wide distribution and sales network through partnerships or authorized dealers.

Market leaders operating in the market have undertaken various organic growth strategies in the Percutaneous Mechanical Circulatory Support Devices  Market. The Percutaneous Mechanical Circulatory Support Devices  market majorly consists of the players such as Abbott,Medtronic, Getinge AB,Teleflex Incorporated, Livanova  Plc (Cardiacassist, Inc.)., Abiomed,Eurosets, Berlin Heart, Jarvik Heart, Inc., CardioBridge GmbH and Company among others. Several organic approaches, such as product launches, and expansion/relocation in the percutaneous mechanical circulatory support devices  Market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.

Below is the list of the growth strategies done by the players operating in the Percutaneous Mechanical Circulatory Support Devices  market:

Year

News

October, 2018

Abbott received approval for the HeartMate 3 Left Ventricular Assist Device (LVAD) as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.

January, 2017

Abbott completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. The company is likely to be benefitted with the acquisition in terms of product portfolio diversification, and develop a strong pipeline of cardiovascular and neuromodulator patient care..

June,2016

Medetronic has launched a product namely Beacon, a care management service for high-risk heart failure patients. This service combines data from Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) devices with post-acute monitoring from MCMS.

August, 2016

Medtronic completed acquisition of HeartWare International, Inc., a leading innovator of less-invasive, miniaturized, mechanical circulatory support technologies (MCS) for treating patients with advanced heart failure. HeartWare will become part of the Heart Failure business within the Medtronic Cardiac Rhythm and Heart Failure division.

 

 

Leave a Reply

Your email address will not be published.